In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia.
Thrombocytopenia is typically observed in patients undergoing hematopoietic stem cell transplantation. We hypothesized that delayed platelet count recovery might be ameliorated by increasing the number of megakaryocyte colony- forming units (CFU-Meg) in the hematopoietic cell graft. To test this hypothesis, we evaluated cytokine combinations and culture medium potentially useful for expanding CFU-Meg in vitro. We then examined the ability of expanded cells to accelerate platelet recovery in an animal transplant model. Depending on the cytokine combination used, we found that culturing marrow CD34+ cells for 7 to 10 days in serum-free cultures was able to expand CFU-Meg approximately 40 to 80 times over input number. Shorter incubation periods were also found to be effective and when CD34+ cells were exposed to thrombopoietin (TPO), kit ligand (KL), interleukin-1alpha (IL-1alpha), and IL-3 in serum-free cultures for as few as 48 hours, the number of assayable CFU-Meg was still increased approximately threefold over input number. Of interest, cytokine primed marrow cells were also found to form colonies in vitro more quickly than unprimed cells. The potential clinical utility of this short-term expansion strategy was subsequently tested in an in vivo animal model. Lethally irradiated Balb-C mice were transplanted with previously frozen syngeneic marrow mononuclear cells (10(6)/mouse), one tenth of which (10(5)) had been primed with [TPO, KL, IL-1a, and IL-3] under serum-free conditions for 36 hours before cryopreservation. Mice receiving the primed frozen marrow cells recovered their platelet and neutrophil counts 3 to 5 days earlier than mice transplanted with unprimed cells. Mice which received marrow cells that had been primed after thawing but before transplantation had similar recovery kinetics. We conclude that pretransplant priming of hematopoietic cells leads to faster recovery of all hematopoietic lineages. Equally important, donor cell priming before transplant may represent a highly cost-effective alternative to constant administration of cytokines during the posttransplant recovery period.
Ratajczak
M Z
MZ
Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Ratajczak
J
J
Machalinski
B
B
Mick
R
R
Gewirtz
A M
AM
D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000379:methods*; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured / Q000637:transplantation; D016895:Culture Media, Serum-Free; D005240:Feasibility Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology; D008533:Megakaryocytes / Q000637:transplantation; D051379:Mice; D008807:Mice, Inbred BALB C; D010976:Platelet Count; D011828:Radiation Chimera; D019089:Stem Cell Factor / Q000494:pharmacology*; D013921:Thrombocytopenia / Q000209:etiology / Q000517:prevention & control*; D013926:Thrombopoietin / Q000494:pharmacology*; D014183:Transplantation, Heterologous
D018952:Antigens, CD34; D016895:Culture Media, Serum-Free; D007377:Interleukin-3; D019089:Stem Cell Factor; D015847:Interleukin-4; D013926:Thrombopoietin